CPRXAnother day, another deal lawyer
Catalyst Pharmaceuticals’ planned sale to Angelini Pharma is attracting fresh attention, this time from Monteverde & Associates PC, which says it’s investigating whether the transaction is fair to shareholders. The deal on the table would hand Catalyst investors $31.50 per share in cash, which sounds tidy — until the plaintiff bar starts circling like seagulls at a boardwalk fry stand.
Why investors should care
When a buyout draws multiple fairness investigations, it doesn’t necessarily mean the deal is broken. But it does mean shareholders may be bracing for more legal chatter, more disclosure pressure, and possibly a slower, messier path to the finish line.
- The core question: is $31.50 per share enough, or is Catalyst being sold a little too cheaply?
- The new investigation adds to the already growing stack of buyout-related legal scrutiny.
- If enough noise builds, it can raise the odds of supplemental disclosures, settlement talk, or just plain deal fatigue.
Big picture
For Catalyst holders, this is less about a dramatic business pivot and more about the usual M&A soap opera: a cash deal, a fairness check, and a parade of law firms asking, “Are we sure this price is right?” Big picture: the buyout is still the main event, but the legal overhang is officially part of the show.